Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

TRimetazidine for acUte on Chronic Liver Failure STudy (TRUST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03737448
Recruitment Status : Recruiting
First Posted : November 9, 2018
Last Update Posted : January 2, 2020
Sponsor:
Information provided by (Responsible Party):
Martin Pharmaceuticals

Brief Summary:
The study will assess the pharmacokinetics (PK), tolerability, and safety of oral trimetazidine administered to subjects with AD (ACLF Grade 0) or with ACLF Grade 1 or 2.

Condition or disease Intervention/treatment Phase
Acute-On-Chronic Liver Failure Drug: Trimetazidine Phase 1

Detailed Description:

The study will assess the PK, tolerability, and safety of oral trimetazidine administered to subjects with acute-on-chronic (ACLF) Grades 1 and 2 with liver failure and a range of renal function. Subjects will receive up to 60 mg/day for 28 days.

Two groups of subjects will be enrolled:

Group 1

  • AD with serum creatinine ≥ 1 and < 2 mg/dL, OR
  • ACLF 1 with

    • liver failure and serum creatinine ≥ 1.5 and < 2 mg/dl, or
    • liver failure and West Haven grade 1-2 hepatic encephalopathy, or
    • coagulation failure and serum creatinine ≥ 1.5 and < 2 mg/dl, or
    • coagulation failure and West Haven grade 1-2 hepatic encephalopathy, OR
  • ACLF 2 with

    • liver failure and coagulation failure, or
    • liver failure and West Haven grade 3-4 hepatic encephalopathy.

Group 2

  • ACLF 1 with renal failure (serum creatinine ≥ 2.0 and < 3.5 mg/dL), OR
  • ACLF 2 with

    • liver failure and renal failure (serum creatinine ≥ 2.0 and < 3.5 mg/dL), or
    • coagulation failure and renal failure (serum creatinine ≥ 2.0 and < 3.5 mg/dL).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Phase 1b Open-Label Study Assessing the Pharmacokinetics, Tolerability, and Safety of Oral Trimetazidine in Subjects With Acute-on-Chronic Liver Failure
Actual Study Start Date : November 28, 2018
Estimated Primary Completion Date : February 28, 2020
Estimated Study Completion Date : June 30, 2020

Arm Intervention/treatment
Experimental: Group 1
  • AD with serum creatinine ≥ 1 and < 2 mg/dL, OR
  • ACLF 1 with

    • liver failure and serum creatinine ≥ 1.5 and < 2 mg/dl, or
    • liver failure and West Haven grade 1-2 hepatic encephalopathy, or
    • coagulation failure and serum creatinine ≥ 1.5 and < 2 mg/dl, or
    • coagulation failure and West Haven grade 1-2 hepatic encephalopathy, OR
  • ACLF 2 with

    • liver failure and coagulation failure, or
    • liver failure and West Haven grade 3-4 hepatic encephalopathy.
Drug: Trimetazidine
Subjects with receive up to 60 mg daily

Experimental: Group 2
  • ACLF 1 with renal failure (serum creatinine ≥ 2.0 and < 3.5 mg/dL), OR
  • ACLF 2 with

    • liver failure and renal failure (serum creatinine ≥ 2.0 and < 3.5 mg/dL), or
    • coagulation failure and renal failure (serum creatinine ≥ 2.0 and < 3.5 mg/dL).
Drug: Trimetazidine
Subjects with receive up to 60 mg daily




Primary Outcome Measures :
  1. plasma pharmacokinetics [ Time Frame: 28 days ]
    Cmax

  2. plasma pharmacokinetics [ Time Frame: 28 days ]
    AUC


Secondary Outcome Measures :
  1. Incidence of treatment-emergent adverse events [Safety and Tolerability] [ Time Frame: 90 days ]
    Adverse events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age 18 to 75 years, inclusive, at screening.
  2. Stable diagnosis of AD, ACLF Grade 1 or ACLF Grade 2 for no less than 2 days (as determined at the discretion of the investigator)*.
  3. Anticipated duration of hospital stay of at least 7 days.
  4. For Group 1:

    • AD with SCr ≥ 1 and < 2 mg/dL, OR
    • ACLF 1 with

      • Tbil ≥ 12 mg/dL, SCr ≥ 1.5 and < 2 mg/dl, and HE 0-2, or
      • Tbil ≥ 12 mg/dL, and SCr < 1.5 mg/dL, and HE 1-2, or
      • INR ≥ 2.5, SCr ≥ 1.5 and < 2 mg/dl, and HE 0-2, or
      • INR ≥ 2.5, SCr < 1.5 mg/dL, and HE 1-2, OR
    • ACLF 2 with

      • Tbil ≥ 12 mg/dL, INR ≥ 2.5, and SCr < 2 mg/dL, or
      • Tbil ≥ 12 mg/dL, HE 3-4, and SCr < 2 mg/dL
  5. For Group 2:

    • ACLF 1 with SCr ≥ 2.0 and < 3.5 mg/dL, OR
    • ACLF 2 with

      • Tbil ≥ 12 mg/dL, and SCr ≥ 2 and < 3.5 mg/dL, or
      • INR ≥ 2.5, and SCr ≥ 2 and < 3.5 mg/dL.
  6. Female patients must be of non-childbearing potential, or, if non-sterile, must agree to sexual abstinence or use a highly effective method of contraception from Screening to 3 days after the final dose.
  7. Non sterile male patients must agree to sexual abstinence or use a highly effective method of contraception from Screening to 3 days after the final dose if sexually active.
  8. Able to comprehend and willing to sign an informed consent form, or, if unable to consent, consent is conducted per local requirements.

Exclusion Criteria:

  1. Diagnosis of AD or ACLF (of any grade) >14 days before enrollment*.
  2. Circulatory failure.
  3. Respiratory failure i.e. PaO2/FiO2 ≤ 200 and/or baseline SpO2/FiO2 ≤ 214.
  4. Brain failure (West Haven grade 3 or 4 hepatic encephalopathy) with coagulation failure (INR > 2.5).
  5. Gastrointestinal bleeding within 72 hours prior to enrollment. (Subjects who fail this criterion may qualify after 72 hours).
  6. Uncontrolled bacterial infection (urinary tract infection, spontaneous bacterial peritonitis, pneumonia, bacteremia, soft tissue infections, etc.) (as determined at the discretion of the investigator).
  7. Invasive fungal infection.
  8. Platelet count <30,000 cells/mL.
  9. White blood cell count <1000 cells/uL.
  10. Patients on hemodialysis or continuous venovenous hemofiltration.
  11. Patients who have undergone or are scheduled for imminent organ transplantation. (Patients may be on a transplant list as long as no date has been set for transplantation)
  12. Hospitalization for ACLF within the 3 months prior to screening.
  13. History of hepatocellular carcinoma, unless within Milan Criteria (up to 3 lesions each < 3 cm or 1 lesion < 5 cm; no extrahepatic involvement; no evidence of gross vascular invasion).
  14. Active non-hepatic malignancy.
  15. Parkinson's disease, Parkinsonian-type symptoms (gait disorder, tremor, etc.), restless leg syndrome or other movement disorders other than asterixis.
  16. Fulminant Wilson's, fulminant autoimmune hepatitis, or Budd-Chiari syndrome.
  17. Septic shock (hypotension requiring vasopressors to maintain a mean arterial pressure of 65 mm Hg or greater and having a serum lactate level greater than 2 mmol/L (> 18 mg/dL) after adequate fluid resuscitation.
  18. Patients who have undergone placement of a transjugular intrahepatic portosystemic shunt (TIPS) or surgical shunt in the past 6 months.
  19. Any invasive procedure within 48 hours prior to enrollment with high risk of uncontrolled bleeding (as determined at the discretion of the investigator).
  20. Female with a positive pregnancy test or lactating.
  21. Positive results for human immunodeficiency virus HIV-1 or HIV-2.
  22. Current treatment with trimetazidine.
  23. Known allergy to trimetazidine or excipients.
  24. Currently receiving an investigational treatment.
  25. Any condition that, in the opinion of the Investigator (or designee), would limit the subject's ability to complete or participate in this clinical study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03737448


Contacts
Layout table for location contacts
Contact: Ann C. Tunstall, PhD 7039818338 ann@martinpharmaceuticals.com

Locations
Show Show 24 study locations
Sponsors and Collaborators
Martin Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Chief Medical Officer Martin Pharmaceuticals
Layout table for additonal information
Responsible Party: Martin Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03737448    
Other Study ID Numbers: MP-0614-001
First Posted: November 9, 2018    Key Record Dates
Last Update Posted: January 2, 2020
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Failure
Hepatic Insufficiency
End Stage Liver Disease
Acute-On-Chronic Liver Failure
Liver Diseases
Digestive System Diseases
Liver Failure, Acute
Trimetazidine
Vasodilator Agents